Skip to content

Study · Randomized controlled trial · n = 88 · 2023

3 results

Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes.

Silver HJ, Olson D, Mayfield D, Wright P, Nian H, Mashayekhi M, Koethe JR, Niswender KD, Luther JM, Brown NJ

Diabetes, obesity & metabolism15 May 2023Cited by 77 (Europe PMC)

PMID37188932 (opens in a new tab)PMCIDPMC10544709 (opens in a new tab)DOI10.1111/dom.15113 (opens in a new tab)PepBankPUB-37188932
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with obesity and prediabetes, 22% of the liraglutide group lost at least 5% of body weight, versus 44% with caloric restriction and 5% with sitagliptin (p = 0.02).

    In plain wordsIn adults with obesity and prediabetes, 22% lost 5% or more of body weight on liraglutide, versus 44% on caloric restriction and 5% on sitagliptin.

    Peptide
    Liraglutide
    Outcome
    MixedWeight loss of 5% or more
    Study

    n = 88

    Comparator
    Caloric restriction; sitagliptin
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.8 mg/d · 14 weeksAs given in this study (human).

    Measurements

    Proportion with weight loss of 5% or more
    22%
    liraglutide

    Source sentences

    Summary
    Weight loss ≥5% of baseline body weight occurred in 44% of participants in the CR group, 22% of the liraglutide group and 5% of the sitagliptin group (p = 0.02).
    1 context sentence
    Summary · context
    A total of 88 adults with obesity and prediabetes were randomized to 14 weeks of intervention with CR (-390 kcal/d), liraglutide (1.8 mg/d), or the dipeptidyl peptidase-4 inhibitor sitagliptin (100 mg/d) as a weight-neutral comparator.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with obesity and prediabetes, the ratio of fat to lean mass fell by 2.2% with liraglutide, versus 6.5% with caloric restriction and 0% with sitagliptin (p = 0.02).

    In plain wordsIn adults with obesity and prediabetes, the fat to lean mass ratio fell 2.2% on liraglutide, less than the 6.5% fall with caloric restriction.

    Peptide
    Liraglutide
    Outcome
    DecreaseFat to lean mass ratio
    Study

    n = 88

    Comparator
    Caloric restriction; sitagliptin
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.8 mg/d · 14 weeksAs given in this study (human).

    Measurements

    Change in fat to lean mass ratio
    −2.2%
    liraglutide

    Source sentences

    Summary
    The ratio of fat to lean mass decreased by 6.5% in the CR group, 2.2% in the liraglutide group, and 0% in the sitagliptin group (p = 0.02).
    1 context sentence
    Summary · context
    A total of 88 adults with obesity and prediabetes were randomized to 14 weeks of intervention with CR (-390 kcal/d), liraglutide (1.8 mg/d), or the dipeptidyl peptidase-4 inhibitor sitagliptin (100 mg/d) as a weight-neutral comparator.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with obesity and prediabetes, visceral fat fell by 4.8% with liraglutide, versus 9.5% with caloric restriction and 0% with sitagliptin (p = 0.04).

    In plain wordsIn adults with obesity and prediabetes, visceral fat fell 4.8% on liraglutide, less than the 9.5% fall with caloric restriction.

    Peptide
    Liraglutide
    Outcome
    DecreaseVisceral fat
    Study

    n = 88

    Comparator
    Caloric restriction; sitagliptin
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.8 mg/d · 14 weeksAs given in this study (human).

    Measurements

    Change in visceral fat
    −4.8%
    liraglutide

    Source sentences

    Summary
    Visceral fat reduced by 9.5% in the CR group, 4.8% in the liraglutide group, and 0% in the sitagliptin group (p = 0.04).
    1 context sentence
    Summary · context
    A total of 88 adults with obesity and prediabetes were randomized to 14 weeks of intervention with CR (-390 kcal/d), liraglutide (1.8 mg/d), or the dipeptidyl peptidase-4 inhibitor sitagliptin (100 mg/d) as a weight-neutral comparator.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 ongoing · source ClinicalTrials.gov (opens in a new tab)

RecruitingPhase not statedNCT07858864

GLP-1 Receptor Agonist Use and Sarcopenia in Obese Individuals Without Diabetes

Istanbul Saglik Bilimleri Universityn = 4230 May 2026 to est. 30 Nov 2026

Obesity · Sarcopenia

Trial pageClinicalTrials.govUpdated 8 Oct 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.